ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced dosing of the first patient in the company’s Phase 1 study evaluating ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer that is typically caused by the Merkel cell polyomavirus (MCPyV). 

Please refer to the following website for further details: 

https://www.biospace.com/article/releases/immunomic-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-of-iti-3000-pdna-vaccine-for-the-treatment-of-merkel-cell-carcinoma/?s=67